Aurora Spine Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study
Carlsbad, Calif, June 28, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a...
Neuroscience
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
Results Show Positive Treatment Effect of CT1812 on Global and Regional Brain Activity Management Holding Webcast Conference Call at 8:00am...
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...
Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte...
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase...
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Long-time Collaborators Botond Roska and José-Alain Sahel Win International Prize for Translational Neuroscience
J-A. Sahel (left)_B.Roska (right) J-A. Sahel (left)_B.Roska (right)Basel, Switzerland, June 22, 2023 --In recognition of their pioneering work on restoring...
BrainsWay Announces Significant Expansion in Western and Central U.S.
30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS NetworkBURLINGTON, Mass. and JERUSALEM, June 21, 2023 (GLOBE NEWSWIRE) --...
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE...
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches
PURCHASE, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that...
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
The Company expands technology for patients with obsessive-compulsive disorderMALVERN, Pa., June 12, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM),...
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical...
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of...
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination biweekly regimen showed...
Janssen Presents First Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first...
Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development
CALGARY, Alberta, June 02, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA)...
Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences
PURCHASE, N.Y., June 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that...
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company...
Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan
Lower Medication Requirement Helps Depression Patients Obtain Treatment SoonerMALVERN, Pa., May 26, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM),...
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with...